Pharming Group N.V. - ADR Aktie News

Pharming Group has transitioned from a speculative play to a fundamentally attractive, cash-generating rare disease company. PHAR delivered $376M in FY2025 revenue, up 27% YoY, surpassing guidance, and generated $44M in operating cash flow, supporting financial independence. Key near-term catalysts include FDA approval for Joenja's pediatric label and pivotal data from leniolisib and KL1333 cli...

Pharming Group N.V. (PHAR) Analyst/Investor Day Transcript

Biotech stock Pharming was pummeled Monday after the FDA rejected the company's request to expand the patient pool for Joenja.

Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with ac...

Pharming Group N.V. ( PHAR ) Q3 2025 Earnings Call November 6, 2025 7:30 AM EST Company Participants Fabrice Chouraqui - CEO & Executive Director Stephen Toor - Chief Commercial Officer & GM Americas Anurag Relan - Chief Medical Officer Kenneth Lynard - Chief Financial Officer Conference Call Participants Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Lucy-Emma Codrington-Bartlett - ...

Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company's growth.